NextBioMedical Co

NextBioMedical Co Operating Cash Flow

The Operating Cash Flow of NextBioMedical Co (389650.KQ) as of Oct 23, 2026 is 1.25 B KRW. In the previous year, Operating Cash Flow was -1.20 B KRW — a change of -204.13% (higher).

Operating Cash Flow

1.25 BKRW

YoY

-204.13%

Last updated:

Operating Cash Flow of NextBioMedical Co is 2025 1.25 B KRW. Operating Cash Flow of NextBioMedical Co was 2024 -1.20 B KRW. It decreases by -204.13% higher compared to the previous year.

The NextBioMedical Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2021
-5.40 B KRW
Jan 1, 2022
-8.21 B KRW
Jan 1, 2023
-4.16 B KRW
Jan 1, 2024
-1.20 B KRW
Jan 1, 2025
1.25 B KRW
The NextBioMedical Co Operating Cash Flow history
YEAROperating Cash FlowYoY
1.25 BKRW-204.13%
-1.20 BKRW-71.14%
-4.16 BKRW-49.32%
-8.21 BKRW+52.11%
-5.40 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Operating Cash Flow of NextBioMedical Co is 1.25 B KRW in 2025.

Operating Cash Flow of NextBioMedical Co changed from -1.20 B KRW to 1.25 B KRW, representing a -204.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's NextBioMedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NextBioMedical Co

All Key Metrics — NextBioMedical Co